Skip to content
To the full analysis

Elevance Health stock: balance sheet and debt

ELV
$429.90Closing price of 12 Nov 2026MEQIRI Score 69 out of 100

Elevance Health has a debt to equity ratio of 0.75 and an interest coverage of 5.8x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.75
Interest coverage
5.8x
Current ratio
1.24
Cash & equivalents
$9.49B
Total assets
$121.49B
Equity ratio
36.2%
Goodwill
$28.34B
Plus intangible assets of $11.2B
Net debt
$23.74B

Total assets and equity ratio

How large the balance sheet of Elevance Health Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$51.76B$22.78B$13.38B47.5%$4.41B
2007$52.06B$22.66B$13.44B44.2%$6.28B
2008$48.4B$22.29B$13.46B44.3%$6.66B
2009$52.13B$21.52B$13.26B47.7%$3.58B
2010$51.28B$21.26B$13.26B46.4%$7.16B
2011$53.26B$21.79B$13.86B43.7%$7.64B
2012$60.21B$25.56B$16.89B39.5%$12.5B
2013$60.49B$25.36B$16.92B40.9%$12.91B
2014$62.93B$25.04B$17.08B38.5%$12.89B
2015$63.06B$25.72B$17.56B36.5%$13.75B
2016$66.39B$25.53B$17.56B37.8%$11.65B
2017$71.46B$27.6B$19.23B37.1%$16.32B
2018$72.47B$29.51B$20.5B39.4%$15.28B
2019$78.25B$29.17B$20.5B40.5%$16.27B
2020$88.28B$31.1B$21.69B37.6%$16.1B
2021$97.46B$34.84B$24.23B37.1%$20.01B
2022$102.76B$34.7B$24.38B35.4%$18.41B
2023$108.93B$35.59B$25.32B36.2%$20.13B
2024$116.89B$40.37B$28.28B35.4%$24.41B
2025$121.49B$39.54B$28.34B36.2%$23.74B

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$2.6B$24.58B$7.01B0.29
2007$2.77B$22.99B$9.04B0.39
2008$2.18B$21.43B$8.84B0.41
2009$4.82B$24.86B$8.4B0.34
2010$1.79B$23.81B$8.95B0.38
2011$2.2B$23.29B$9.84B0.42
2012$2.48B$23.8B$14.98B0.63
2013$1.58B$24.77B$14.49B0.59
2014$2.15B$24.25B$15.04B0.62
2015$2.11B$23.04B$15.86B0.69
2016$4.08B$25.1B$15.73B0.63
2017$3.61B$26.5B$19.93B0.75
2018$3.93B$28.54B$19.21B0.67
2019$4.94B$31.73B$21.21B0.67
2020$5.74B$33.2B$21.84B0.66
2021$4.88B$36.06B$24.89B0.69
2022$7.39B$36.24B$25.8B0.71
2023$6.53B$39.31B$26.65B0.68
2024$8.29B$41.32B$32.7B0.79
2025$9.49B$43.88B$33.24B0.75

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026, previously Strong
  • Valuation signal Undervalued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy